Skip to content
← Childhood Soft Tissue Sarcoma

HEALTH PROFESSIONAL · SOURCE READING

Genomic alterations

Source: Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 21, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Tumors of Uncertain Differentiation / Desmoplastic Small Round Cell Tumor

Cytogenetic studies of these tumors have demonstrated the recurrent translocation t(11;22)(p13;q12), which has been characterized as a fusion of the WT1 and EWSR1 genes.[105,108] The EWSR1::WT1 fusion confirms the diagnosis of desmoplastic small round cell tumor. The average tumor variant burden is low for desmoplastic small round cell tumor (<1 variant per megabase), and recurring gene alterations other than the EWSR1::WT1 fusion are uncommon.[109] A small percentage of cases (approximately 3%) have activating variants in FGFR4, with amplification of FGFR4 observed at similar frequency.[109,110] Inactivating variants in TP53 and ARID1A are observed in a small percentage of desmoplastic small round cell tumor cases.[109,110]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice